Apr 3, 2008 by Brian Orelli, PhDWellPoint Won't PayThe insurance giant refuses to pay for doctors' mistakes.
Apr 2, 2008 by Brian Orelli, PhDAbraxis Tardy, but With a NoteAbraxis finally gets around to releasing fourth-quarter 2007 financials.
Apr 1, 2008 by Brian Orelli, PhDBreeding Crickets for Fun and ProfitIf the recession gets really bad, I hear they're high in protein.
Mar 31, 2008 by Brian Orelli, PhDFoolish Forecast: Can Monsanto Make Its Growth Last?Views you can use to get clues on tomorrow's news.
Mar 31, 2008 by Brian Orelli, PhDCollateral Damage From an FDA WarningBioMimetic gets hit hard by a warning about a J&J drug.
Mar 31, 2008 by Brian Orelli, PhDNo Blood-Pumping Love for Merck and ScheringMerck and Schering don't heart the ACC.
Mar 31, 2008 by Brian Orelli, PhDNow Is Not the Time to Wimp Out on BiotechDon't jump ship just because developmental-stage drugmakers are getting walloped.
Mar 28, 2008 by Brian Orelli, PhDThe Yin and Yang of Schering's Label ChangesSchering gets a pair of label changes that have opposite effects for its hepatitis C drug.
Mar 28, 2008 by Brian Orelli, PhDWyeth Fires to Get Back on FireThe first round of Wyeth's cuts look like the right move.
Mar 28, 2008 by Brian Orelli, PhDAllergic Reaction to Singulair News?The FDA warns the public about potential side effects of Merck's allergy treatment.
Mar 27, 2008 by Brian Orelli, PhDTougher Rules Could Help Stent MakersNewcomers to the field might not be so happy.
Mar 26, 2008 by Brian Orelli, PhDMonsanto's Guidance Grows Like a WeedThe company has had good reasons to set its sights higher.
Mar 25, 2008 by Brian Orelli, PhDBiovail Hit by a Slow-Moving TruckBiovail finally settles with the SEC.
Mar 24, 2008 by Brian Orelli, PhDAlnylam Authorizes AgainThe pharmaceutical's latest patent-licensing deal isn't immediately lucrative.
Mar 20, 2008 by Brian Orelli, PhDAbbott and Takeda's Partnership TAPed OutIt's a 50/50 split for the drug companies.
Mar 18, 2008 by Brian Orelli, PhDIs Health-Care Insurance Really Sick?Another insurer lowers guidance.
Mar 18, 2008 by Brian Orelli, PhDThe Nuts and Bolts of Drug ResearchMerck makes news with its obesity studies, but companies that sell research tools will benefit, too.
Mar 18, 2008 by Brian Orelli, PhDLack of Side Effects Doesn't Fatten ArenaGood safety data on its obesity drug fails to plump up the stock price.
Mar 18, 2008 by Brian Orelli, PhDDynavax Gets Held UpThe FDA puts a clinical hold on Dynavax's lead program.
